{"doi":"10.1159/000497548","title":"Impact of new diagnostic criteria on the frequency of diabetes mellitus and prediabetic conditions","abstract":"<jats:p>The American Diabetes Association (ADA) approved new diagnostic criteria for diabetes mellitus in\n1997. Altering the diagnostic criteria may result in variable effects on the prevalence of diabetes. In this\nstudy, we aimed to evaluate the difference between World Health Organisation (WHO) and ADA\ncriteria in practice and the impact of new criteria on the frequency of diabetes mellitus and prediabetic\nconditions in patients who need to have their glucose metabolism evaluated.\n\nTwo hundred and fifty patients (182 females and 68 males, age 53.1 ± 11.6 years) who were not known\nto be diabetic were studied. Subjects with a fasting plasma glucose level of 110 mg/dl and above, or\nwith a fasting plasma glucose of 100-109 mg/dl and a risk factor were included in the study. An oral\nglucose tolerance test with 75 g glucose was performed on all patients. The diagnoses of diabetes,\nimpaired glucose tolerance (IGT) and impaired fasting glucose (IFG) as defined by two different sets of\ncriteria were compared.\n\nWhen patients were evaluated according to WHO criteria, 115 patients (46.0 %) had normal glucose\ntolerance, 76 (30.4 %) had IGT and 59 (23.6 %) were diabetic. When patients were evaluated according\nto ADA criteria, only 19 patients (7.6 %) had normal glucose tolerance, 52 (20.8 %) had IGT, 113\n(45.2 %) had diabetes mellitus (DM) and 66 (26.4 %) patients had IFG. There is an important\ndifference in the diagnosis of patients (κ=0.45). The most striking difference is in the group that has\nfasting plasma glucose between 110-125 mg/dl, especially because of the definition of IFG in the new\ncriteria.\n\nIn conclusion, use of the ADA criteria caused an evident change in the frequency of diabetes mellitus\nand prediabetic conditions in the study population. These results suggest that the new criteria are more\nsensitive and useful in diagnosing diabetes and especially prediabetic conditions, and also can be\napplied more easily. This study only considers patients who needed the evaluation of glucose\nmetabolism. Further studies are needed to evaluate the change in frequency in similar populations.</jats:p>","journal":"International Journal of Diabetes and Metabolism","year":2019,"id":632629,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1639922,"name":"A. Gökhan Özgenb","orcid":null,"position":1,"is_corresponding":false},{"id":1639924,"name":"Gürcan Kısakolb","orcid":null,"position":2,"is_corresponding":false},{"id":1639919,"name":"Engin Güney","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Impact of new diagnostic criteria on the frequency of diabetes mellitus and prediabetic conditions","abstract":"<jats:p>The American Diabetes Association (ADA) approved new diagnostic criteria for diabetes mellitus in\n1997. Altering the diagnostic criteria may result in variable effects on the prevalence of diabetes. In this\nstudy, we aimed to evaluate the difference between World Health Organisation (WHO) and ADA\ncriteria in practice and the impact of new criteria on the frequency of diabetes mellitus and prediabetic\nconditions in patients who need to have their glucose metabolism evaluated.\n\nTwo hundred and fifty patients (182 females and 68 males, age 53.1 ± 11.6 years) who were not known\nto be diabetic were studied. Subjects with a fasting plasma glucose level of 110 mg/dl and above, or\nwith a fasting plasma glucose of 100-109 mg/dl and a risk factor were included in the study. An oral\nglucose tolerance test with 75 g glucose was performed on all patients. The diagnoses of diabetes,\nimpaired glucose tolerance (IGT) and impaired fasting glucose (IFG) as defined by two different sets of\ncriteria were compared.\n\nWhen patients were evaluated according to WHO criteria, 115 patients (46.0 %) had normal glucose\ntolerance, 76 (30.4 %) had IGT and 59 (23.6 %) were diabetic. When patients were evaluated according\nto ADA criteria, only 19 patients (7.6 %) had normal glucose tolerance, 52 (20.8 %) had IGT, 113\n(45.2 %) had diabetes mellitus (DM) and 66 (26.4 %) patients had IFG. There is an important\ndifference in the diagnosis of patients (κ=0.45). The most striking difference is in the group that has\nfasting plasma glucose between 110-125 mg/dl, especially because of the definition of IFG in the new\ncriteria.\n\nIn conclusion, use of the ADA criteria caused an evident change in the frequency of diabetes mellitus\nand prediabetic conditions in the study population. These results suggest that the new criteria are more\nsensitive and useful in diagnosing diabetes and especially prediabetic conditions, and also can be\napplied more easily. This study only considers patients who needed the evaluation of glucose\nmetabolism. Further studies are needed to evaluate the change in frequency in similar populations.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":null,"license":"https://karger.com/pages/terms-and-conditions","oa_locations":[{"url":"https://karger.com/ijd/article-pdf/10/1/22/4128101/000497548.pdf","host_type":"publisher"},{"url":"https://karger.com/article-pdf/doi/10.1159/000497548","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":[],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T10:05:29.998937Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}